Genome Editing for Familial Hemophagocytic Lymphohistiocytosis: Design Principles, Challenges, and Translational Perspectives
Human Gene Therapy · 2026
DOI: 10.1177/10430342261465555 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Human Gene Therapy, 2026. Verfasst von Ghazale Minaiyan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Transfusion Medicine and Gene Therapy, Medical Center-University of Freiburg, Freiburg, Germany. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic, Gene Editing, Genetic Therapy. Die Arbeit nennt 112 Literaturangaben. Gefördert von: Histiocytosis Association, Deutscher Akademischer Austauschdienst, HORIZON EUROPE Framework Programme.
Abstract (Originalsprache)
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome caused by genetic defects in cytotoxic lymphocyte function. Current therapies can control disease activity, but transplantation of allogeneic hematopoietic stem and progenitor cells (HSPCs) remains the only curative option and is associated with substantial risks. These limitations have accelerated development of genome editing approaches enabling precise correction of disease-causing mutations in autologous cells. Familial HLH (FHL) represents a compelling target for genome editing, but successful and safe clinical translation has remained challenging. Preclinical studies demonstrate that targeted editing of key genes, such as PRF1 and UNC13D , can restore cytotoxic function in HSPCs and T cells. Translation to the clinic, however, depends on multiple factors, including the choice of target cell population, the level of functional correction required, and gene-specific constraints such as locus complexity and regulation of gene expression. In this review, we synthesize current progress in genome editing for FHL and highlight critical biological and technical barriers to clinical implementation. We propose a conceptual framework for designing genome editing strategies tailored to FHL, emphasizing the alignment of editing platform, gene architecture, and cellular context to enable effective and clinically translatable therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Transfusion Medicine and Gene Therapy, Medical Center-University of Freiburg, Freiburg, Germany.
- Center for Chronic Immunodeficiency (CCI), Medical Center-University of Freiburg, Freiburg, Germany.
- PhD Program, Faculty of Biology, University of Freiburg, Freiburg, Germany.
- Faculty of Medicine, University of Freiburg, Freiburg, Germany.
ORCID-Profile: Ghazale Minaiyan, Toni Cathomen
Förderung
- Histiocytosis Association
- Deutscher Akademischer Austauschdienst
- HORIZON EUROPE Framework Programme
Zitieren
APA
Minaiyan, G., Aussel, C., Ammann, S., & Cathomen, T. (2026). Genome Editing for Familial Hemophagocytic Lymphohistiocytosis: Design Principles, Challenges, and Translational Perspectives. Human Gene Therapy. https://doi.org/10.1177/10430342261465555
Vancouver
Minaiyan G, Aussel C, Ammann S, Cathomen T. Genome Editing for Familial Hemophagocytic Lymphohistiocytosis: Design Principles, Challenges, and Translational Perspectives. Human Gene Therapy. 2026. doi:10.1177/10430342261465555
BibTeX
@article{Minaiyan2026,
author = {Minaiyan, Ghazale and Aussel, Clotilde and Ammann, Sandra and Cathomen, Toni},
title = {Genome Editing for Familial Hemophagocytic Lymphohistiocytosis: Design Principles, Challenges, and Translational Perspectives},
journal = {Human Gene Therapy},
year = {2026},
doi = {10.1177/10430342261465555}
}
EUVIMED